MedPath

Cabergoline

CABERGOLINE TABLETS Rx only

Approved
Approval ID

275a6a25-c3c9-4258-a610-0b00752517f7

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 15, 2023

Manufacturers
FDA

SOLA Pharmaceuticals, LLC

DUNS: 080121345

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

cabergoline

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70512-860
Application NumberANDA076310
Product Classification
M
Marketing Category
C73584
G
Generic Name
cabergoline
Product Specifications
Route of AdministrationORAL
Effective DateMay 15, 2023
FDA Product Classification

INGREDIENTS (5)

CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
CABERGOLINEActive
Quantity: 0.5 mg in 1 1
Code: LL60K9J05T
Classification: ACTIB
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cabergoline - FDA Drug Approval Details